Malondialdehyde in benign prostate hypertrophy: a useful marker?

Author： Pasquale Giuseppe Di   Tomaino Antonio   Minciullo Paola Lucia   Fraccica Giuseppe   Gangemi Sebastiano   Merendino Rosaria Alba   Salvo Francesco   Saija Antonella  

Publisher： Informa Healthcare

ISSN： 1466-1861

Source： Mediators of Inflammation, Vol.12, Iss.2, 2003-01, pp. : 127-128

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

MANAGEMENT OF BENIGN HYPERTROPHY OF THE PROSTATE

By  

JOURNAL OF AMERICAN GERIATRICS SOCIETY, Vol. 2, Iss. 6, 1954-06 ,pp. : 400-404

John Wiley & Sons Inc

Access to resources Recommend Favorite

Testosterone Levels in Benign Prostatic Hypertrophy and Prostate Cancer

By  

Urologia Internationalis, Vol. 80, Iss. 2, 2008-03 ,pp. : 134-140

Karger

Access to resources Recommend Favorite

Malondialdehyde: A Possible Marker of Ageing

By  

Gerontology, Vol. 48, Iss. 4, 2002-06 ,pp. : 209-214

Karger

Access to resources Recommend Favorite

Electrovaporization of the Prostate versus Laser Ablation of the Prostate in Men with Benign Prostatic Hypertrophy:A Pressure-Flow Analysis

By  

Urologia Internationalis, Vol. 60, Iss. 4, 1998-08 ,pp. : 224-228

Karger

Access to resources Recommend Favorite

MMP13 can be a useful differentiating marker between squamous cell carcinoma and benign hyperkeratotic lesions in recessive dystrophic epidermolysis bullosa

By  

BRITISH JOURNAL OF DERMATOLOGY, Vol. 172, Iss. 3, 2015-03 ,pp. : 769-773

John Wiley & Sons Inc

Access to resources Recommend Favorite